Comparison

JTC-801 European Partner

Item no. S2722-5
Manufacturer Selleckchem
CASRN 244218-51-7
Amount 5 mg
Quantity options 10 mg 1 g 10 g 10 mM/1 ml 5 mg 50 mg 5 g
Category
Type Inhibitors
Specific against other
Smiles CCC1=CC=C(C=C1)OCC2=CC=CC=C2C(=O)NC3=CC4=C(C=C(N=C4C=C3)C)N.Cl
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias Opioid receptor-like1 (ORL1),Opioid Receptor
Similar products JTC-801
Available
Storage Conditions
2 years -80 in solvent
Molecular Weight
447, 96
Administration
Orally or injected i.v.
Animal Models
Male ICR (CD-1) subjected to nociceptin-induced allodynia test or hot plate test, and Male SD rats subjected to formalin-induced paw-licking response
Dosages
ca.10 mg/kg
Formulation
Suspended in 0.5% methyl cellulose solution or dissolved in 5% sorbitol
IC50
94 nM [1], 94 nM [1], 94 nM [1], 94 nM [1], 94 nM [1], 94 nM [1]
In vitro
JTC-801 displays about 12.5-, 129-, and 1055-fold selectivity for ORL1 receptor (Ki = 8.2 nM) over u-, kappa-, and delta-opioid receptors, respectively. JTC-801 does not inhibit forskolin-stimulated cyclic AMP accumulation in human ORL1 receptor-expressing HeLa cells, but it prevents nociceptin-induced inhibition of cyclic AMP accumulation, indicating that JTC-801 possesses full antagonistic activity. [2] In rat cerebrocortical membrane, JTC-801 inhibits ORL1 receptor with IC50 of 472 nM and u-receptor with IC50 of 1831 nM. JTC-801 completely antagonizes the suppression of nociceptin on forskolin-induced accumulation of cyclic AMP with IC50 of 2.58 uM in HeLa cells expressing ORL1 receptor. [1]
In vivo
Oral administration of JTC-801 (0.3-3 mg/kg) antagonizes nociceptin-induced allodynia in mice, and shows analgesic effect in a hot plate test using mice and in a formalin test using rats. [2] In mouse hot-plate test, JTC-801 prolongs escape response latency (ERL) or exposed heat stimulus with minimum effective doses (MED) of 0.01 mg/kg by i.v. or 1 mg/kg by p.o. In the rat formalin test, JTC-801 reduces both the first and second phases of the nociceptive response with MED of 0.01 mg/kg71 by i.v. or 1 mg/kg by p.o. [1] JTC-801 dose-dependently normalizes paw withdrawal latency (PWL). Although JTC-801 does not inhibit a chronic constriction injury (CCI)-induced decrease in bone mineral content (BMC) and bone mineral density (BMD), it inhibits an increase in the number of osteoclasts. [3] Tactile allodynia induced by L5/L6 spinal nerve ligation is reversed by both systemic (3-30 mg/kg) and spinal (22.5 and 45 pg) JTC-801 in a dose-dependent manner. Furthermore, systemic JTC-801 reduces Fos-like immunoreactivity in the dorsal horn of the spinal cord (laminae I/II). [4] JTC-801 produces dose-dependent mechanical and cold anti-allodynic effects with ED50 of 0.83 mg/kg and 1.02 mg/kg, respectively. [6]
Kinase Assay
Human ORL1 receptor binding affinity, Human ORL1 receptor expressed in HeLa cells are harvested and homogenized in 50 mM Tris buffer (pH 7.4) containing 1 mM EDTA. After centrifugation for 30 minutes at 40, 000g, the pellets are resuspended in buffer containing 50 mM Tris, supplemented with 10 mM MgCl2 and 2 mM EGTA, and used as membrane preparations. 50 mM Tris (pH 7.4) supplemented with 2 mM EDTA and 0.1 mM (p-amidoinophenyl) methanesulphonyl fluoride hydrochloride containing 0.2% bovine serum albumin is used for the binding buffer. For saturation binding assay, the cell membrane preparations are incubated for 60 minutes at 24 C with various concentrations of [3H]-nociceptin. Nonspecific binding is determined in the presence of 1 mM unlabelled nociceptin. For competitive assay, the cell membrane preparations (4.17 ug/well) are incubated for 60 minutes at 24 C with 50 pM [3H]-nociceptin in the presence of various concentrations of JTC-801 (10 nM-10 uM). JTC-801 is dissolved in DMSO and diluted in binding buffer, and then added to the incubation mixture. Final concentration of vehicle is 1% DMSO in binding buffer. After incubation for 60 minutes, the membrane preparations are rapidly filtrated over Whatman GF/B glass filters which are pretreated with 0.1% polyethyleneimine, and the radioactivity on each filter is measured by liquid scintillation counting. IC50 value is calculated as the concentration of JTC-801 required to displace 50% inhibition of the [3H]-nociceptin.
Solubility (25C)
DMSO 90 mg/mL, Water <1 mg/mL, Ethanol 31 mg/mL
Information
JTC-801 is a selective opioid receptor-like1 (ORL1) receptor antagonist with IC50 of 94 nM, weakly inhibits receptors δ, κ, and μ.
Chemical Name
N-(4-amino-2-methylquinolin-6-yl)-2-((4-ethylphenoxy)methyl)benzamide hydrochloride

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 5 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?